As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Connect Biopharma Holdings Ltd. The largest reported stake is Panacea Innovation Limited's, at 21.2%. 13 filings are on record since July 21, 2025 (Schedule 13D/A, April 1, 2026).
Sell to companies like Connect Biopharma Holdings Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Qiming Managing Directors Fund V, L.P. · Sole voting: 54,826 · Shared voting: 0 · Sole dispositive: 54,826 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-03
- · Reporting person: BML Investment Partners, L.P. · Sole voting: 0 · Shared voting: 3,864,400 · Sole dispositive: 0 · Shared dispositive: 3,864,400 · SCHEDULE 13G, 2026-10-06
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 4,338,534 · Sole dispositive: 0 · Shared dispositive: 4,338,534 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Wei Zheng · Sole voting: 2,520,359 · Shared voting: 0 · Sole dispositive: 2,520,359 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Wei Zheng · Percent: 6.2% · SCHEDULE 13G/A
Connect Biopharma Holdings Ltd has 13 Schedule 13D or 13G filings on record since 2025-07-21. 4 holders' latest filing reports 5% or more of ordinary shares, par value us$0.000174 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Panacea Innovation Limited | 21.2% | 13,160,000 | SCHEDULE 13D/A, 2026-04-01 | 2026-03-31 |
| 9.6% | 6,026,813 | SCHEDULE 13G, 2026-04-14 | 2026-04-14 | |
| Ikarian Capital, LLC | 6.9% | 4,338,534 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 6.77% | 4,264,400 | SCHEDULE 13G, 2026-10-06 | 2026-09-30 | |
| 4% | 2,520,359 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| Qiming Corporate GP V, Ltd. | 2.9% | 1,821,426 | SCHEDULE 13G/A, 2026-11-03 | 2026-09-30 |
Holding shares or following this stake? See who's behind Connect Biopharma Holdings Ltd and the warning signs.
Free to see. No signup.
Keep reading
More on Connect Biopharma Holdings Ltd and the records around it.
Connect Biopharma Holdings Ltd elsewhere on the record
Companies that share a holder
- Panacea Innovation Limited also filed stake reports on 3 other companies: Atara Biotherapeutics, Inc. (May 2026), CASI Pharmaceuticals, Inc. (Dec 2025), Adagene Inc. (Nov 2025)
- BML Investment Partners, L.P. also filed stake reports on 15 other companies: LENZ Therapeutics, Inc. (Nov 2026), Seer, Inc. (Nov 2026), Outset Medical, Inc. (Oct 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Galera Therapeutics, Inc. (Aug 2026), InMed Pharmaceuticals Inc. (Aug 2026)
Watch Connect Biopharma Holdings Ltd
Get an email when Connect Biopharma Holdings Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Connect Biopharma Holdings Ltd?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Connect Biopharma Holdings Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Connect Biopharma Holdings Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 0 | 4,338,534 | 0 | 4,338,534 | SCHEDULE 13G/A, 2026-08-14 |
| Neil Shahrestani | 0 | 4,338,534 | 0 | 4,338,534 | SCHEDULE 13G/A, 2026-08-14 |
| BML Investment Partners, L.P. | 0 | 3,864,400 | 0 | 3,864,400 | SCHEDULE 13G, 2026-10-06 |
| Braden M Leonard | 400,000 | 3,864,400 | 400,000 | 3,864,400 | SCHEDULE 13G, 2026-10-06 |
| Wei Zheng | 2,520,359 | 0 | 2,520,359 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Qiming Managing Directors Fund V, L.P. | 54,826 | 0 | 54,826 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming Venture Partners V, L.P. | 1,766,600 | 0 | 1,766,600 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming Corporate GP V, Ltd. | 1,821,426 | 0 | 1,821,426 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming GP V, L.P. | 1,766,600 | 0 | 1,766,600 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming GP VII, LLC | 935,064 | 0 | 935,064 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming Venture Partners VII, L.P. | 926,527 | 0 | 926,527 | 0 | SCHEDULE 13G/A, 2026-11-03 |
| Qiming VII Strategic Investors Fund, L.P. | 8,537 | 0 | 8,537 | 0 | SCHEDULE 13G/A, 2026-11-03 |
The latest filing identifies Connect Biopharma Holdings Ltd by CUSIP G23549101 and gives its principal executive office as 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130 (SCHEDULE 13G/A, 2026-11-03).
Purpose of Transaction (Item 4)
Panacea Innovation Limited
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Securities Purchase Agreement On March 29, 2026, Panacea Venture Healthcare Fund II, L.P., together with certain other investors, entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, pursuant to which the Issuer agreed to sell an aggregate of 6,130,000 Ordinary Shares (the "Offering"). Pursuant to the Securities Purchase Agreement, Panacea Venture Healthcare Fund II, L.P. purchased 1,160,000 Ordinary Shares at a price of $3.45 per Ordinary Share. The Offering closed on March 31, 2026. Pursuant to the Securities Purchase Agreement, the Issuer agreed to file a registration statement with the Securities and Exchange Commission within 45 days after the closing of the Offering covering the resale of the Ordinary Shares issued to the investors pursuant to the Securities Purchase Agreement. Additionally, James Huang has agreed not to sell or otherwise dispose of any Ordinary Shares held by him for a period ending 45 days after the closing of the Offering (the "Lock-up Agreement") without first obtaining the written consent of the Placement Agents (as defined in the Securities Purchase Agreement). The Lock-up Agreement is included as Exhibit A to the Securities Purchase Agreement. The foregoing description of the Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Securities Purchase Agreement, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-01; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | Panacea Innovation Limited | 25.1% | SCHEDULE 13D/A |
| 2025-11-26 | Panacea Innovation Limited | 21.5% | SCHEDULE 13D/A |
| 2025-11-28 | Wei Zheng | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 8.8% | SCHEDULE 13G |
| 2026-02-17 | Zheng Wei | 9% | SCHEDULE 13G/A |
| 2026-02-17 | Wubin Pan | 10.8% | SCHEDULE 13G/A |
| 2026-04-01 | Panacea Innovation Limited | 21.2% | SCHEDULE 13D/A |
| 2026-04-14 | Wubin Pan | 9.6% | SCHEDULE 13G |
| 2026-05-15 | Wei Zheng | 6.2% | SCHEDULE 13G/A |
| 2026-08-14 | Ikarian Capital, LLC | 6.9% | SCHEDULE 13G/A |
| 2026-08-14 | Wei Zheng | 4% | SCHEDULE 13G/A |
| 2026-10-06 | Braden M Leonard | 6.77% | SCHEDULE 13G |
| 2026-11-03 | Qiming Corporate GP V, Ltd. | 2.9% | SCHEDULE 13G/A |
Questions about who owns Connect Biopharma Holdings Ltd
Who owns Connect Biopharma Holdings Ltd?
On this page, 4 holders' latest ownership filings report 5% or more of Connect Biopharma Holdings Ltd: Panacea Innovation Limited (21.2%, Schedule 13D/A, filed 2026-04-01), Wubin Pan (9.6%, Schedule 13G, filed 2026-04-14), Ikarian Capital, LLC (6.9%, Schedule 13G/A, filed 2026-08-14) and Braden M Leonard (6.77%, Schedule 13G, filed 2026-10-06).
Who are the largest shareholders of Connect Biopharma Holdings Ltd?
By the share each holder's latest filing reports, the largest holders of Connect Biopharma Holdings Ltd on this page are Panacea Innovation Limited (21.2%), Wubin Pan (9.6%) and Ikarian Capital, LLC (6.9%).
When did Panacea Innovation Limited buy into Connect Biopharma Holdings Ltd?
The filings give report dates, not purchase dates. The earliest filing from Panacea Innovation Limited on this page is the Schedule 13D/A, filed 2025-07-21, reporting 25.1%; its latest, Schedule 13D/A filed 2026-04-01, reports 21.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Connect Biopharma Holdings Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.